First, HZZO could periodically review reimbursement criteria for GLP-1-based and SGLT-2 therapies to ensure that coverage prioritizes patients at the highest cardiovascular-, renal- or obesity-related risk, thereby maximizing clinical value per euro spent. This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.